Page last updated: 2024-11-07

cyproterone acetate, ethinyl estradiol drug combination

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107694
MeSH IDM0101767

Synonyms (11)

Synonym
3'h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-, mixt. with (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol
shb 209 ae
diane
diane-35
diane-35 diario
cyproterone acetate - ethinyl estradiol
60528-19-0
cyproterone acetate, ethinyl estradiol drug combination
1-acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate--19-norpregna-1(10),2,4-trien-20-yne-3,17-diol (1/1)
DTXSID40975940
[(1s,2s,5r,11r,12s,15r,16s)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" A multicenter study was therefore done, in which two preparations containing CA in combination with ethinylestradiol (EE) were compared with a marketed combined oral contraceptive pill."( Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study.
Carlborg, L, 1986
)
0.27
"To compare the effects of 3 therapeutic regimens widely used in practice--OHC alone and in combination with metformin or rosiglitazone on body weight and anthropometric proportions, hormonal and metabolic alterations."( [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Atanasova, I; Genchev, G; Kamenov, Z; Khristov, V; Kolarov, G; Milcheva, B; Orbetsova, M; Shigarminova, R; Zakharieva, S, 2006
)
0.33
"To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
"Diane-35 in combination with orlistat or metformin is more effective in reducing androgen than Diane-35 alone."( Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018
)
0.48
"To evaluate the effects of Chinese medicine Dingkun Pill () alone or in combination with Diane-35 on patients with polycystic ovary syndrome (PCOS)."( Is There An Advantage of Using Dingkun Pill () alone or in Combination with Diane-35 for Management of Polycystic Ovary Syndrome? A Randomized Controlled Trial.
Deng, Y; Ma, RL; Ma, X; Sun, AJ; Wang, YF; Xue, W; Zhu, SY, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."( On therapeutic approaches to some special types of acne.
Rajka, G, 1985
)
0.27
" One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA."( A comparative study of Aldactone and Diane in the treatment of hirsutism.
Djøseland, O; Lunde, O, 1987
)
0.27
" It has been postulated that a threshold dosage of CPA has mutagenic effects, but in the same way data have been published documenting that a continuous low dosage of cyproterone acetate leads to a reduction of mutagenic episodes."( [Long-term side-effects following cyproterone acetate containing therapy in gynecology].
Regidor, M; Regidor, PA; Schindler, EM; Speer, K, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (142)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (23.24)18.7374
1990's24 (16.90)18.2507
2000's33 (23.24)29.6817
2010's45 (31.69)24.3611
2020's7 (4.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.04 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index73.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (33.33%)5.53%
Reviews9 (6.00%)6.00%
Case Studies13 (8.67%)4.05%
Observational2 (1.33%)0.25%
Other76 (50.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females [NCT04964193]24 participants (Actual)Interventional2019-03-12Completed
A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of Polycystic Ovary Syndrome [NCT03264638]Phase 2315 participants (Anticipated)Interventional2016-10-01Recruiting
The Effect of Two Combined Oral Contraceptives Containing Cyproterone Acetate or Drospirenone on Blood Metabolomics in Women With Polycystic Ovary Syndrome [NCT04831151]42 participants (Anticipated)Interventional2021-03-01Recruiting
The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants [NCT02027337]Phase 4200 participants (Anticipated)Interventional2013-12-31Recruiting
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization [NCT01752270]Phase 4100 participants (Anticipated)Interventional2012-12-31Not yet recruiting
[NCT01784380]1,159 participants (Actual)Observational2006-10-31Completed
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Progestin-insensitive Early-stage Endometrial Cancer and Atypical Hyperplasia Patients With Conservative Treatment [NCT05316935]Phase 2/Phase 3118 participants (Anticipated)Interventional2022-07-13Recruiting
Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study [NCT02410031]759 participants (Actual)Observational2015-06-26Completed
Evaluation of Periodontal Status and High Sensitivity C Reactive Protein Levels in Female Patients Diagnosed With Polycystic Ovary Syndrome on Cyproterone Acetate/Ethinyl Estradiol Combination Regimen: a Cross Sectional Study [NCT05021861]150 participants (Anticipated)Observational2021-11-30Not yet recruiting
Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases [NCT02349399]26,065 participants (Actual)Observational2015-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter
NCT04964193 (2) [back to overview]Pharmacokinetics Parameter

Pharmacokinetics Parameter

Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg*hr/mL (Mean)
AUC0-t of Cyproterone AcetateAUC0-t of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet127.54842.56
Elzsa Film-coated Tablet132.56870.45

[back to top]

Pharmacokinetics Parameter

Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing

,
Interventionpg/mL (Mean)
Cmax of Cyproterone AcetateCmax of Ethinyl Estradiol
Diane-35 Sugar-coated Tablet16.2093.61
Elzsa Film-coated Tablet17.39103.69

[back to top]